global Osteoarthritis Therapeutics market was valued at $11,200.0 million in 2025 and is projected to reach $24,744.3 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026-2035). The growing burden of arthritis-related disability is a critical driver shaping demand in the osteoarthritis therapeutics market, as functional impairment significantly increases the need for sustained medical intervention. According to the US Centers for Disease Control and Prevention, an estimated 58.5 million adults aged 18 years and older in the US have arthritis, underscoring the scale of the affected population. Of these individuals, 25.7 million report arthritis-attributable activity limitations, reflecting substantial disease impact on daily functioning and quality of life. Projections further indicate that by 2040, approximately 34.6 million adults with arthritis are expected to experience activity limitations, indicating a worsening disability burden over time.
Browse the full report description of “Global Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, By Anatomy (Knee, Ankle, Hip, Hand, and Spine), By Drug Type (NSAIDs, Viscosupplementation Agents, Corticosteroids, and Analgesics) and Forecast, 2026-2035” at https://www.omrglobal.com/industry-reports/osteoarthritis-therapeutics-market
This rising prevalence of functional impairment reinforces demand for long-term pharmacologic therapies aimed at pain control, inflammation reduction, and mobility preservation. As activity limitations progress, patients typically require more intensive and prolonged treatment regimens, increasing lifetime therapeutic utilization. These trends directly support market expansion for osteoarthritis drugs, including non-steroidal anti-inflammatory drugs, injectable therapies, and emerging disease-modifying agents. Additionally, growing disability prevalence encourages earlier treatment initiation and closer disease monitoring, extending treatment duration.
Innovation Leaders Transforming the Osteoarthritis Therapeutics Market
The key players in the osteoarthritis therapeutics market include Pfizer Inc., Bayer AG, Sanofi, Haleon plc, Kenvue Inc., among others. These companies are driving innovation in the global osteoarthritis therapeutics market through the development of disease-modifying drug candidates, advanced biologics, and novel intra-articular therapies aimed at slowing joint degeneration and improving long-term function. Ongoing advances in targeted mechanisms of action, combination approaches, and clinical trial design are supporting evolving treatment needs, unmet disease-modification goals, and improved patient outcomes across global healthcare markets.
Market Coverage
Key questions addressed by the report.
Global Osteoarthritis Therapeutics Market Report Segment
By Anatomy
By Drug Type
Global Osteoarthritis Therapeutics Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/osteoarthritis-therapeutics-market